- Home
- NBP vs ZTR Comparison
NBP vs ZTR Comparison
Compare NBP & ZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBP | ZTR |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | 32 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.3M | 357.2M |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | NBP | ZTR |
|---|---|---|
| Price | $2.90 | $6.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 657.5K | 228.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.81 | $5.22 |
| 52 Week High | $5.19 | $7.11 |
Technical Indicators
Market Signals| Indicator | NBP | ZTR |
|---|---|---|
| Relative Strength Index (RSI) | 37.17 | 51.91 |
| Support Level | N/A | $6.71 |
| Resistance Level | $3.90 | $7.11 |
| Average True Range (ATR) | 0.32 | 0.08 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 13.97 | 31.09 |
Price Performance
Historical ComparisonAbout NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.